Celcuity Inc
0.0 %
-20.79 %
Yet to be announced
Company Overview
Celcuity Inc. is a clinical stage biotechnology company focused on developing targeted therapies for cancer patients. The company uses its CELsignia diagnostic platform technology to identify new groups of cancer patients likely to benefit from specific targeted therapies and drugs.
The company is currently in the development and clinical trial phase and has not yet commercialized any products. Their main focus is on developing diagnostic tests and therapies for breast cancer patients.
Revenue Sources
As Celcuity is currently a pre-revenue company focused on research and development of cancer treatments, with no commercial products on the market yet, this criteria is not applicable at this stage. The company's planned future revenue will come from legitimate medical treatments and diagnostics, which are halal activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Since Celcuity is still in the pre-revenue research and development phase, we do not apply the standard interest ratios. The company does have interest expenses from its financing activities, which is typical for pre-revenue biotech companies funding their research and development activities. Given the pre-revenue stage of the company, these interest expenses are considered part of the startup phase rather than the company's core business model.
Operational Ethics
Based on review of the company's SEC filings and public information, there is no evidence of any significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, with no identified R&D centers or significant business relationships in Israel or direct ties to the Chinese Communist Party.
Login to join the discussion